Gyre Therapeutics (GYRE) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.65% |
| Dec 31, 2025 | 6.87% |
| Sep 30, 2025 | 1.62% |
| Jun 30, 2025 | 3.51% |
| Mar 31, 2025 | 1.35% |
| Dec 31, 2024 | 7.56% |
| Sep 30, 2024 | 3.91% |
| Jun 30, 2024 | 0.05% |
| Mar 31, 2024 | -3.45% |
| Dec 31, 2023 | -34.97% |
| Sep 30, 2023 | -8.07% |
| Jun 30, 2023 | -10.77% |
| Mar 31, 2023 | -11.55% |
| Dec 31, 2022 | 18.60% |
| Sep 30, 2022 | 3.38% |
| Jun 30, 2022 | 21.11% |
| Mar 31, 2022 | 14.38% |
| Dec 31, 2021 | 29.91% |
| Sep 30, 2021 | 25.38% |
| Jun 30, 2021 | 29.39% |
| Mar 31, 2021 | 30.04% |
| Dec 31, 2020 | 19.34% |
| Sep 30, 2020 | 21.04% |
| Jun 30, 2020 | 1.83% |
| Mar 31, 2020 | -1.13% |
| Dec 31, 2019 | 21.29% |
| Sep 30, 2019 | -6.36% |
| Jun 30, 2019 | -4.47% |
| Mar 31, 2019 | -3.14% |
| Dec 31, 2018 | 25.91% |
| Sep 30, 2018 | -2.40% |
| Jun 30, 2018 | -2.84% |
| Mar 31, 2018 | -3.36% |
| Dec 31, 2017 | 18.43% |
| Sep 30, 2017 | -33.45% |
| Jun 30, 2017 | -31.17% |
| Mar 31, 2017 | -40.05% |
| Dec 31, 2016 | -37.92% |
| Sep 30, 2016 | -35.96% |
| Jun 30, 2016 | -34.11% |
| Dec 31, 2015 | -19.31% |